

ARRAY BIOPHARMA INC  
Form 8-K  
March 08, 2004

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

## FORM 8-K

### CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 8, 2004**

### **Array BioPharma Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other  
Jurisdiction of  
Incorporation)

**000-31979**  
(Commission  
File Number)

**84-1460811**  
(IRS Employer  
Identification No.)

**3200 Walnut Street, Boulder, Colorado**  
(Address of Principal Executive Offices)

**80301**  
(Zip Code)

Registrant's telephone number, including area code: **(303) 381-6600**

(Former Name or Former Address, if Changed Since Last Report)

**ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.**

On March 5, 2004, the Registrant issued a press release announcing that it had received notification from the U.S. Food & Drug Administration that its investigational new drug application had become effective for ARRY-142886, the full text of which is attached hereto as Exhibit 99.1.

**ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.**

(c) Exhibits.

99.1 Press release dated March 5, 2004 entitled Array BioPharma's Anticancer Compound ARRY-142886 Cleared To Advance Into Human Clinical Trials

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARRAY BIOPHARMA INC.

Date: March 8, 2004

By:

/s/ Robert E. Conway  
Robert E. Conway  
Chief Executive Officer

**EXHIBIT INDEX**

**Exhibit No.**

99.1 Press release dated March 5, 2004 entitled Array BioPharma's Anticancer Compound ARRY-142886 Cleared To Advance Into Human Clinical Trials